Drug Screening Assays, Antitumor
"Drug Screening Assays, Antitumor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals.
|Drug Screening Assays, Antitumor
- Drug Screening Assays, Antitumor
- Antitumor Drug Screening Assays
- Cancer Drug Tests
- Cancer Drug Test
- Drug Test, Cancer
- Drug Tests, Cancer
- Test, Cancer Drug
- Tests, Cancer Drug
- Drug Screening Tests, Tumor-Specific
- Drug Screening Tests, Tumor Specific
- Antitumor Drug Screens
- Antitumor Drug Screen
- Drug Screen, Antitumor
- Drug Screens, Antitumor
- Screen, Antitumor Drug
- Screens, Antitumor Drug
- Anti-Cancer Drug Screens
- Anti Cancer Drug Screens
- Anti-Cancer Drug Screen
- Drug Screen, Anti-Cancer
- Drug Screens, Anti-Cancer
- Screen, Anti-Cancer Drug
- Screens, Anti-Cancer Drug
- Anticancer Drug Sensitivity Tests
- Tumor-Specific Drug Screening Tests
- Tumor Specific Drug Screening Tests
Below are MeSH descriptors whose meaning is more general than "Drug Screening Assays, Antitumor".
Below are MeSH descriptors whose meaning is more specific than "Drug Screening Assays, Antitumor".
This graph shows the total number of publications written about "Drug Screening Assays, Antitumor" by people in this website by year, and whether "Drug Screening Assays, Antitumor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Drug Screening Assays, Antitumor" by people in Profiles.
Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics. Adv Drug Deliv Rev. 2022 03; 182:114111.
A pan-cancer organoid platform for precision medicine. Cell Rep. 2021 07 27; 36(4):109429.
1,3-Benzodioxole-Modified Noscapine Analogues: Synthesis, Antiproliferative Activity, and Tubulin-Bound Structure. ChemMedChem. 2021 09 16; 16(18):2882-2894.
Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. Eur J Med Chem. 2021 Nov 15; 224:113672.
Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on av Integrins. J Mol Biol. 2021 07 23; 433(15):167090.
Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat Commun. 2020 10 19; 11(1):5271.
Targeted Covalent Inhibition of Telomerase. ACS Chem Biol. 2020 03 20; 15(3):706-717.
Oral Mucosal Organoids as a Potential Platform for Personalized Cancer Therapy. Cancer Discov. 2019 07; 9(7):852-871.
Multi-target, ensemble-based virtual screening yields novel allosteric KRAS inhibitors at high success rate. Chem Biol Drug Des. 2019 08; 94(2):1441-1456.
Design and synthesis of new substituted spirooxindoles as potential inhibitors of the MDM2-p53 interaction. Bioorg Chem. 2019 05; 86:598-608.